...
首页> 外文期刊>Acta odontologica Scandinavica. >Randomized controlled clinical trial on the efficacy of dentin desensitizing agents
【24h】

Randomized controlled clinical trial on the efficacy of dentin desensitizing agents

机译:牙本质脱敏剂疗效的随机对照临床试验

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective. To investigate the effects of four dentin desensitizers on pain reduction in hypersensitive cervical dentin lesions. Materials and methods. The trial was designed as a randomized, controlled, four-arm, single-masked study. Fifty subjects with at least one hypersensitive lesion in each of the four quadrants were allocated. The requested pre-operative pain, determined as a response to 2-s air-blast (AB) and probe scratching (PS), was >= 5 on a VAS scale, 0 = no through to 10 = worst pain. Randomly each subject received each of the four treatments: MS Coat One F (MSC, Sun Medical, Japan), Nanoseal (NAN, Nishin, Japan), Teethmate Desensitizer (TMD, Kuraray Noritake, Japan) and Gluma Desensitizer PowerGel (GLU, HeraeusKulzer, Germany). The investigator assessed blindly the pain response using the two stimuli and recorded the patients' VAS scores before and immediately after application, after 1 week and after 1, 3 and 6 months. Statistical data treatment. ANOVA and post-hoc testing (p <= 0.05). Results. Forty-nine subjects completed the trial. Pre-operative dentin hypersensitivity (DH) for the groups was not significantly different. All desensitizers reduced DH significantly throughout the 6-months observation. ANOVA revealed significant differences among VAS scores, obtained with the desensitizing agents (p < 0.001). Ranking by post-hoc testing was: MSC > NAN > TMD > GLU (p < 0.05). Upon PS NAN and TMD showed slight but significant regain of sensitivity after 6 months. For GLU PS scores immediately after application and after 6 months were not significantly different, whereas recalls after 1 week, 1 month and 3 months revealed significantly lower scores. Conclusion. The calcium phosphate-based TMD and GLU proved highly effective in reducing sensitivity.
机译:目的。调查四种牙本质脱敏剂对过敏性宫颈牙本质病灶减轻疼痛的作用。材料和方法。该试验设计为随机,对照,四臂单掩盖研究。分配了在四个象限的每一个中具有至少一个超敏病变的五十个受试者。在VAS评分标准上,要求的术前疼痛(以对2-s鼓风(AB)和探针刮擦(PS)的反应确定)> = 5,0 =从无到10 =最严重的疼痛。每个受试者随机接受以下四种治疗方法中的每一种:MS Coat One F(MSC,日本Sun Medical),Nanoseal(NAN,Nishin,日本),Teethmate脱敏剂(TMD,日本Kuraray Noritake)和Gluma脱敏剂PowerGel(GLU,HeraeusKulzer) ,德国)。研究人员使用两种刺激盲法评估了疼痛反应,并记录了患者在应用前后,1周后,1、3和6个月后的VAS评分。统计数据处理。方差分析和事后检验(p <= 0.05)。结果。四十九名受试者完成了试验。各组的术前牙本质过敏(DH)没有显着差异。在整个6个月的观察中,所有脱敏剂均显着降低DH。方差分析显示使用脱敏剂获得的VAS评分之间存在显着差异(p <0.001)。事后测试的排名是:MSC> NAN> TMD> GLU(p <0.05)。在PS后,NAN和TMD在6个月后显示出轻微但显着的敏感性恢复。施用后立即和6个月后的GLU PS评分无显着差异,而1周,1个月和3个月后的召回率则显着降低。结论。磷酸钙基TMD和GLU被证明在降低灵敏度方面非常有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号